• Biocon Biologics, Viatris get EC approval for biosimilar Bevacizumab expresspharma
    April 27, 2021
    Abevmy 100 and 400 mg is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer, non small-cell lung carcinoma, glioblastoma, ovarian, cervical and renal cancer as part of a specific regimen.
  • Biocon Biologics and Viatris get CHMP Nod for Abevmy expresspharma
    March 01, 2021
    Biocon Biologics, a subsidiary of Biocon announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the marketing authoris ation of their biosimilar Bevacizumab ...
PharmaSources Customer Service